| Patient | Benny Leonard |
|---|---|
| Date of birth | 1976-04-07 |
| Identifiers | MRN HR-BX008-SYN; SSN (made up) 000-08-4106 |
| Document date | 2026-10-27 |
| Author | Miriam Okafor-Rosenthal, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Twenty-four-week review: blood pressure, work, mood, worry and aspirin. [S]
Mr. Leonard returns six months after intake. He has refereed full cards each week and taught his classes without breathlessness, chest tightness, palpitations or lightheadedness. His home readings over the past week averaged 120/76 mmHg. He takes losartan, amlodipine and atorvastatin every day; the ankle puffiness is slight. He feels less worried about money and sleeps better. He asked again about aspirin, which the cardiologist had raised. [S]
| Element | Detail |
|---|---|
| Home blood pressure | Average 120/76 mmHg over seven days |
| Mood and worry | PHQ-9 2; GAD-7 3 |
| Work | Full cards weekly without symptoms |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest discomfort, palpitations, fainting or breathlessness at work |
| Gastrointestinal | Negative | No indigestion, black stools or bleeding |
| Psychiatric | Negative | Mood good; less worry; sleeping six to seven hours |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Losartan 50 mg with hydrochlorothiazide 12.5 mg, one tablet each morning | One tablet each morning | Oral route | 2026-05-12 to 2026-06-30 | completed | S |
| Losartan 100 mg with hydrochlorothiazide 25 mg, one tablet each morning | One tablet each morning; held from the sick visit; stopped at the preventive visit | Oral route | 2026-06-30 to 2026-07-28 | stopped | S |
| Atorvastatin 40 mg tablet, one each evening | One tablet each evening | Oral route | 2026-05-26 | active | S |
| Losartan 100 mg tablet, one each morning | One tablet each morning; hold on sick days | Oral route | 2026-07-28 | active | S |
| Amlodipine 5 mg tablet, one each morning | One tablet each morning | Oral route | 2026-07-28 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-27 | Body height | 165 | cm | S |
| 2026-10-27 | Body weight | 73 | kg | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 26.8 | kg/m2 | S |
| 2026-10-27 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-10-27 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-27 | Heart rate | 66 | /min | S |
| 2026-10-27 | Respiratory rate | 14 | /min | S |
| 2026-10-27 | Body temperature | 36.5 | Cel | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 2026-10-27 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | {score} | S |
Vital signs recorded on 2026-10-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 122/76 mmHg, pulse 66; weight 73.0 kg |
| Cardiovascular | Regular rhythm; no murmur; trace ankle edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness and tightness across the chest on exertion for about two months, late in long nights of refereeing in hot arenas, easing within a few minutes of rest; never at rest; no fainting, palpitations, orthopnea or ankle swelling; cause under evaluation with a cardiology consultation | resolved | confirmed | R06.09 | S — Synthetic presenting problem anchored to his documented work as a referee; superseded at the consultation when stress testing showed no ischemia and the symptom was attributed to hypertensive heart disease. |
| Stage 2 hypertension found at a yearly fitness examination for his referee's license (164/100 and 160/98 mmHg), with left ventricular hypertrophy by voltage on the ECG; untreated; home readings to follow | resolved | confirmed | I10 | S — Synthetic diagnosis at intake; reclassified as hypertensive heart disease after the echocardiogram at the consultation. |
| Hypertensive heart disease without heart failure: concentric left ventricular hypertrophy (septum 13 mm, mass index 118 g/m2) with normal ejection fraction, grade 1 diastolic dysfunction, a mildly enlarged left atrium and an exaggerated blood pressure rise on exercise; no features of hypertrophic cardiomyopathy | active | confirmed | I11.9 | S — Synthetic diagnosis made at the cardiology consultation; not a claim about his real heart. |
| Coronary atherosclerosis found by coronary calcium scoring (Agatston score 186, about the 80th percentile for his age and sex), without angina and with no inducible ischemia on exercise stress echocardiography | active | confirmed | I25.10 | S — Synthetic diagnosis made at the cardiology consultation; not a retrospective diagnosis of the cause of his death, which is disputed. |
| Hypercholesterolemia: LDL 160 mg/dL, HDL 44 mg/dL, lipoprotein(a) not raised; no diabetes | active | confirmed | E78.00 | S — Synthetic diagnosis at intake. |
| Volume depletion after refereeing a long card in a heat wave while taking losartan 100 mg with hydrochlorothiazide 25 mg: lightheaded on standing, with an orthostatic fall in blood pressure, a prerenal rise in creatinine to 1.44 mg/dL and potassium 3.3 mmol/L; no fainting, chest pain or arrhythmia | resolved | confirmed | E86.0 | S — Synthetic acute problem from the thiazide in summer heat; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Clinic blood pressure, average of two seated readings | Every visit | Completed today | 122/76 mmHg |
| Self-management | Home blood pressure monitoring (validated upper-arm cuff), readings sent weekly | Every day during titration; then a week before each visit | Completed today | Seven-day average 120/76 mmHg |
| Laboratory | Basic metabolic panel (sodium, potassium, creatinine, eGFR) | Two to four weeks after starting or changing an ARB or diuretic; then every six months | Up to date | Normal two months ago; next in about four months |
| Laboratory | Urine albumin-to-creatinine ratio | At diagnosis, then yearly | Up to date | Due a year after intake |
| Laboratory | HbA1c | At diagnosis, then yearly | Up to date | Due a year after intake |
| Laboratory | Lipid panel | Four to twelve weeks after starting a statin; then yearly | Up to date | LDL 66 mg/dL; next a year after starting atorvastatin |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension or suspected hypertrophy; repeat in six to twelve months to judge regression | Due | Repeat in about six months, a year after the first |
| Imaging | Stress testing or coronary imaging | For new or changed exertional symptoms; not for routine surveillance | Not indicated | No symptoms; routine surveillance testing is not recommended |
| Examination | Symptoms: exertional chest discomfort, breathlessness, palpitations, fainting | Every visit | Completed today | None |
| Examination | Weight, BMI and physical activity | Every visit | Completed today | 73.0 kg, BMI 26.8; brisk walks most mornings |
| Medication safety | Adherence and side effects (cough, edema, muscle aches, lightheadedness) | Every visit | Completed today | No missed doses; trace ankle edema only |
| Medication safety | Aspirin decision | When risk changes | Completed today | Shared decision: not started, by his choice; revisit yearly |
| Self-management | Return to work: refereeing, heat and hydration, warning symptoms, defibrillator at the venue | Before return to full exertion; then every visit | Completed today | Full cards weekly without symptoms |
| Survey | Depression screen (PHQ-9) | At intake, then yearly or with change | Completed today | 2, from 5; item 9 scored 0 |
| Survey | Anxiety screen (GAD-7) | At intake, then yearly or with change | Completed today | 3, from 6 |
| Self-management | Financial strain and medicine cost | Every visit | Completed today | Three generic medicines at low cost; money steadier |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2; Recombinant zoster vaccine, dose 2 of 2; Influenza vaccine, inactivated trivalent, this season's formulation [S]
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (2026); 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease (2019); Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (2015); CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and ischemic heart disease monographs (2026); Depression and Suicide Risk in Adults: Screening (2023); Anxiety Disorders in Adults: Screening (2023); Adult Immunization Schedule by Age (2026)
Follow-up: Second hepatitis B and zoster doses and the influenza vaccine today; COVID-19 vaccine at the pharmacy. Basic metabolic panel and urine albumin in about four months. Echocardiogram and lipid panel in about six months. Next preventive visit in July. [S]